Skyrizi Market Report 2026

Skyrizi Market Overview

• The Skyrizi market growth in the historic period has been driven by increasing diagnosis of autoimmune disorders, limitations of conventional immunosuppressive therapies • Market expansion is supported by increasing expansion into new inflammatory indications, rising investments in next-generation biologics • Growth Driver: Growing Interest In Personalized Medicine Driving The Market Growth • Market Trend: New Hope For UC Patients Unresponsive To Conventional Therapies • North America was the largest region and fastest growing region.

What Is Covered Under Skyrizi Market?

Skyrizi refers to a prescription medication used to treat certain autoimmune conditions, including moderate to severe plaque psoriasis, active psoriatic arthritis, and Crohn's disease, by reducing inflammation in the body. The mechanism of action of skyrizi (risankizumab-rzaa) involves selectively targeting and inhibiting interleukin-23 (IL-23), a protein that plays a key role in inflammatory and immune responses. The main indications for skyrizi include plaque psoriasis, crohn's disease, and ulcerative colitis. Plaque psoriasis refers to a common form of psoriasis marked by raised, red patches covered with silvery-white scales. It typically appears on the scalp, elbows, and knees, causing discomfort and irritation. The various formulations include pre-filled syringes and vials, and they are distributed through several channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Skyrizi Market Growth Forecast?

The growth in the forecast period can be attributed to increasing expansion into new inflammatory indications, rising investments in next-generation biologics, growing patient preference for convenient dosing regimens, increasing healthcare focus on durable remission, expansion of biologic treatment guidelines. Major trends in the forecast period include increasing adoption of il-23 targeted therapies, rising use across multiple autoimmune indications, growing preference for long-dosing interval biologics, expansion of self-administered injectable formats, enhanced focus on long-term disease control.

Global Skyrizi Market Segmentation

1) By Indication: Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis 2) By Formulation: Pre-Filled Syringes, Vials 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Is The Driver Of The Skyrizi Market?

Growing interest in personalized medicine is expected to propel the growth of the skyrizi market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rising personalized medicine is due to advancements in genomic technologies, increased understanding of molecular biology, growing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Skyrizi helps personalized medicine by offering a targeted biologic therapy that specifically inhibits interleukin-23 (IL-23), enabling healthcare providers to tailor treatment for patients with moderate to severe autoimmune diseases, such as psoriasis and ulcerative colitis, based on individual responses and disease characteristics, thereby improving efficacy and minimizing treatment-related side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the growing interest in personalized medicine drives the skyrizi industry.

Key Players In The Global Skyrizi Market

Major companies operating in the skyrizi market are AbbVie Inc.

Global Skyrizi Market Trends and Insights

Major companies operating in the SKYRIZI market are focusing on developing innovative solutions, such as interleukin-23 (IL-23) inhibitor therapies, to meet the rising demand for targeted and highly effective treatments for autoimmune and chronic inflammatory diseases. IL-23 inhibitors work by selectively blocking the p19 subunit of the IL-23 cytokine, which plays a central role in driving inflammatory pathways. This targeted approach offers improved efficacy and safety compared to traditional broad-spectrum immunosuppressants. For instance, in July 2024, AbbVie Inc., a US-based biopharmaceutical company, received European Commission approval for SKYRIZI (risankizumab) for the treatment of adults with moderately to severely active ulcerative colitis who have not responded to, or are intolerant to, conventional or biologic therapies. SKYRIZI is a monoclonal antibody that selectively inhibits IL-23, offering a focused mechanism of action that helps reduce inflammation and promote mucosal healing. The therapy features a 1,200 mg IV induction regimen followed by 180 mg or 360 mg subcutaneous maintenance doses every eight weeks. Clinical evidence from the Phase 3 INSPIRE and COMMAND trials demonstrated strong outcomes, including significant mucosal healing and sustained remission, especially in patients without prior biologic or JAK inhibitor use.

What Are Latest Mergers And Acquisitions In The Skyrizi Market?

In March 2023, AbbVie, a U.S.-based biopharmaceutical company, collaborated with Boehringer Ingelheim to develop and commercialize immunology therapies. With this collaboration, AbbVie capitalizes on Boehringer Ingelheim’s earlier discovery contributions in IL-23 biology while steering Skyrizi’s global market rollout and label expansion. Boehringer Ingelheim is a Germany-based provider of research-driven pharmaceuticals and biologics, including in immunology and inflammation.

Regional Insights

North America was the largest region in the skyrizi market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Skyrizi Market?

The skyrizi market consists of sales of intravenous (IV) infusion for induction and subcutaneous (SC) injection and pen injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Skyrizi Market Report 2026?

The skyrizi market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the skyrizi industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.